Genprex is a technology company.
Genprex has raised $10.0M across 1 funding round.
Genprex has raised $10.0M in total across 1 funding round.
Genprex has raised $10.0M in total across 1 funding round.
Genprex's investors include SproutVest Ltd. Co..
Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing therapies for patients with cancer and diabetes who have limited treatment options.[1][2][3][4][5] Its lead oncology candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), targets non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) using the proprietary non-viral Oncoprex® Delivery System, which delivers tumor suppressor genes via lipid nanoparticles administered intravenously; it has received FDA Fast Track and Orphan Drug Designations.[1][3][5] For diabetes, preclinical programs like GPX-002 use AAV vectors to deliver Pdx1 and MafA genes to the pancreas, aiming to restore insulin production in Type 1 and Type 2 diabetes, with plans to spin out a separate company focused on these assets.[6] Genprex serves large patient populations resistant to standard therapies like Keytruda, partnering with institutions such as MD Anderson and the University of Pittsburgh to advance its pipeline.[1][3][4]
The company demonstrates growth momentum through clinical achievements in Phase 1/2 trials, successful manufacturing of Reqorsa for upcoming NSCLC trials combining it with drugs like Tagrisso and Keytruda, and multiple FDA designations signaling regulatory support.[5][7]
Genprex was co-founded in 2009 in Austin, Texas, by David Nance and Rodney Varner, who acquired the core Reqorsa® technology from a former biotech company post-2008 financial crisis.[3][4][5] Motivated by promising preclinical and clinical data from researchers including oncologist Dr. Jack Roth at MD Anderson Cancer Center, the founders aimed to develop novel gene therapies for cancer and later expanded to diabetes.[4] Early traction came from advancing the non-viral Oncoprex platform—the first systemic gene therapy delivery for cancer in humans—leading to public trading on NASDAQ since 2018 and collaborations with world-class institutions.[3][5][7]
Genprex rides the gene therapy wave, addressing genomic limitations in targeted therapies and immunotherapies for hard-to-treat cancers like NSCLC/SCLC and diabetes, where patients often develop resistance.[3] Timing aligns with surging demand for non-viral and AAV-based therapies, as viral vectors face scalability and safety hurdles; its systemic intravenous approach targets large populations underserved by current options.[1][3] Market forces favoring Genprex include massive unmet needs—lung cancer and diabetes affect millions globally—and regulatory nods like Fast Track, accelerating trials amid biotech's push for combination therapies.[5] By pioneering gene re-expression in tumors and pancreatic regeneration, Genprex influences the ecosystem, bridging academic research with clinical translation and enabling combos with blockbusters like Keytruda.[7]
Genprex is poised for milestones with Reqorsa NSCLC trials underway, diabetes spin-out to unlock focused development, and preclinical optimization of GPX-002/003.[6][7] Trends like immunotherapy combos, non-viral platforms, and direct pancreatic gene delivery will shape its path, potentially yielding approvals in resistant cancers and diabetes by bridging gaps in large markets.[1][3] Its influence may grow through partnerships and Nasdaq visibility, evolving from pipeline builder to therapy provider—transforming limited-option patients' lives as promised since its 2009 origins.[2][4]
Genprex has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series B in September 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2018 | $10.0M Series B | SproutVest Ltd. Co. |